- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04690595
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Katrin Tiemann, PhD
- Phone Number: 626-359-8111
- Email: ktiemann@coh.org
Study Contact Backup
- Name: Ting-Ying (Hazel) Cheng, PhD
- Phone Number: 714-599-8077
- Email: hazel.cheng@pepromenebio.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Ibrahim Aldoss, MD
- Phone Number: 626-218-2405
- Email: ialdoss@coh.org
-
Contact:
- Katrin Tiemann, PhD
- Phone Number: (626) 359-8111
- Email: ktiemann@coh.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative.
- Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study PI approval.
- Age ≥ 18 years.
- ECOG ≤ 2.
- Life expectancy ≥ 16 weeks.
- Histologically confirmed B-ALL or B-cell lymphoblastic lymphoma
- Relapsed/refractory disease after failure of ≥ 2 prior lines of therapy.
- Evidence of active BAFF-R expression at the time of enrollment.
- Recovered to ≤ Grade 1 from the acute toxic effects (except alopecia) of prior anti-cancer therapy.
- No known contraindications to leukapheresis, steroids or tocilizumab.
Ineligible for or failed prior CD19-targeted immunotherapy (e.g., blinatumomab or CD19-CAR T cells).
For participants who had prior CD19-CAR T cell therapy:
- At least 90-days has elapsed since participant received last CD19-CAR T cell therapy.
AND
- Persistence of prior CD19-CAR T cells must be evaluated and found to be <5% prior to leukapheresis procedure
- Participants with CNS involvement by leukemia (CNS2 and asymptomatic CNS3) may be considered eligible after discussions with the study team.
- Total serum bilirubin ≤ULN (unless has Gilbert's disease, then ≤3.0)
- AST ≤ ULN
- ALT ≤ ULN
- Creatinine clearance of ≥ 50 mL/min per 24-hour urine test or the Cockcroft-Gault formula
- Left ventricular ejection fraction (LVEF) ≥ 50%
- O2 saturation ≥ 92% on room air.
Seronegative for HIV Ag/Ab combo, HCV*, and active HBV (Surface Antigen Negative)
*If positive, Hepatitis C RNA quantitation must be performed and must be undetectable.
- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Agreement by females and males of childbearing potential^ to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy.
^Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
- A complete liver evaluation (which includes ultrasound elastography, MRI of the liver and a hepatology consult) may be done if needed based on PI's recommendation.
- Evaluation of acquired hemochromatosis (indicated through MRI of the liver and elevated levels of Ferritin) is recommended for participants who have undergone multiple transfusions and prior alloHCT.
Exclusion Criteria:
- Autologous/allogeneic stem cell transplant within 100 days at the time of enrollment.
- Immunosuppressant medications within 3 months prior to protocol enrollment.
- Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone ≤ 7.5 mg /day or equivalent) is allowed
- Auto-immune disease or active GVHD within 6 months prior to protocol enrollment requiring systemic immunosuppressant therapy.
- Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification.
- Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within 2 weeks of enrollment.
- Any abnormal liver enzyme levels (as defined ≥ULN in ALT, AST, Bilirubin and Alkaline Phosphatase levels) at time of enrollment
- . Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
- Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.
History of venous occlusive disease (VOD), or GvHD.
a. Subjects with a history of the following GvHD may still be included in the study: i. Resolved Grade 2 or less steroid-sensitive acute skin GvHD ii. Grade 1 gastro-intestinal (GI)-GvHD developed within 100 days post prior alloHCT.
- History of stroke or intracranial hemorrhage within 6 months of enrollment.
- History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for ≥ 3 years.
- Clinically significant uncontrolled illness.
- Active systemic uncontrolled infection requiring antibiotics.
- Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.
- Females only: Pregnant or breastfeeding.
- Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAFFR-CAR T cells
B-cell activating factor receptor-Chimeric antigen receptor T cells
|
First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 1 year post treatment
|
Toxicity will be graded per Common Terminology Criteria for Adverse Events version 5.0, Cytokine Release Syndrome (CRS) and neurotoxicity which use the American Society for Transplantation and Cellular Therapy Consensus Criteria (ASTCT) and Graft versus Host Disease (GVHD) criteria.
Toxicities will be followed from the start of lymphodepletion until the end of the study.
|
Up to 1 year post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease response
Time Frame: Up to 1 year post treatment
|
Defined as complete response [CR], or complete response with incomplete blood count recovery [CRi], or complete response with partial hematological recovery [CRh].
Response will be evaluated using European Leukemia Net (ELN) criteria.
Rates and associated 95% binomial exact confidence limits will be estimated (CR/CRi/CRh) rate.
|
Up to 1 year post treatment
|
Minimal residual disease (MRD)
Time Frame: Up to 1 year post treatment
|
Negative MRD is defined by malignant cells < 0.01% by flow cytometry or clonoSEQ.
|
Up to 1 year post treatment
|
B cell frequency
Time Frame: Up to 1 year post treatment
|
Measured by serum IgG level
|
Up to 1 year post treatment
|
Severity of graft-versus-host disease (GVHD) in recipients of prior allogeneic hematopoietic stem cell transplantation
Time Frame: Up to 1 year post treatment.
|
Defined per Keystone criteria for acute GVHD and revised National Institute of Health (NIH) consensus on grading of chronic GVHD.
|
Up to 1 year post treatment.
|
Progression-free survival (PFS)
Time Frame: From T cell infusion to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 15 years.
|
Kaplan-Meier product limit method with log-log transformation for the confidence interval will be used to estimate PFS.
|
From T cell infusion to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 15 years.
|
Overall survival (OS)
Time Frame: From the day of BAFFR-CAR T cell infusion to death from any cause assessed, up to 15 years.
|
Kaplan-Meier product limit method with log-log transformation for the confidence interval will be used to estimate OS.
|
From the day of BAFFR-CAR T cell infusion to death from any cause assessed, up to 15 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ibrahim Aldoss, MD, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMB-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
-
Shenzhen BinDeBio Ltd.Xiangya Hospital of Central South UniversityRecruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.Children's Hospital of Fudan UniversityActive, not recruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Shenzhen BinDeBio Ltd.The First Affiliated Hospital of Zhengzhou UniversityUnknownRefractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory B-cell LymphomaChina
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health HospitalRecruitingRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin LymphomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRelapsed and/or Refractory Acute Lymphoblastic Leukemia | Relapsed and/or Refractory B-cell Non-Hodgkin's LymphomaChina
-
Verastem, Inc.WithdrawnRelapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
-
Autolus LimitedRecruitingRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin LymphomaUnited Kingdom
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnB-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia
-
Michael BurkeAmgenRecruitingRefractory B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic LeukemiaUnited States
-
Novartis PharmaceuticalsCompletedB-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on BAFFR-CAR T cells
-
PeproMene Bio, Inc.City of Hope Medical CenterRecruitingRelapsed or Refractory B-cell Non-Hodgkin's LymphomaUnited States
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina